01—Abstract
Summary
Summary of the 10-K filed February 29, 2012. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. reported strong performance in its 2011 fiscal year, with total revenues reaching $15.58 billiona, a 4% increase from the previous year, driven by robust sales of its key products like Neulasta®/NEUPOGEN®, Enbrel®, and other growing products such as Prolia® and XGEVA®.
The company demonstrated a strong commitment to shareholder returns, initiating its first-ever quarterly cash dividends in 2011 and repurchasing approximately 15% of its outstanding stock for $8.3 billionb. Amgen also made strategic acquisitions, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to expand its pipeline and market reach. However, the company recorded a significant $780 million charge related to an agreement in principle to settle allegations concerning its sales and marketing practices.
Looking ahead, Amgen faced ongoing challenges including increasing competition from biosimilars, patent expirations on key products, and evolving regulatory and reimbursement landscapes. Despite these headwinds, the company expressed confidence in its future growth opportunities driven by its late-stage pipeline and strategic business development initiatives.
02—Key points
Key Highlights
- Total revenues increased by 4% to $15.58 billion in 2011, with product sales driven by key products like Neulasta®/NEUPOGEN® and Enbrel®.
- Amgen initiated quarterly cash dividends in 2011, paying out $500 million and increasing its quarterly dividend by 29% by year-end.
- The company executed a significant share repurchase program, buying back approximately 15% of its outstanding stock for $8.3 billion.
- Strategic acquisitions were made, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to strengthen the product pipeline and market presence.
- A $780 million charge was recorded in relation to an agreement in principle to settle allegations concerning sales and marketing practices.
- Key products like Aranesp® and EPOGEN® experienced sales declines due to regulatory and reimbursement changes, including updated FDA label changes for ESAs.
- The company highlighted strong growth for newer products like Prolia® and XGEVA®, with significant revenue contributions in their initial years of broader market availability.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Amgen Inc kept $0.24.
- Revenue$15.58B100.0%
- Cost of revenue−$2.71B17.4%
- Gross profit$12.87B82.6%
- Operating costs−$8.56B54.9%
- Operating income$4.31B27.7%
- Interest, other & tax−$629.0M4.0%
- Net income$3.68B23.6%
Where FY2011 revenue went
$15.58B- SG&A: $4.50B, 29% of revenue
- Other operating costs: $4.06B, 26% of revenue
- Net income: $3.68B, 24% of revenue
- Cost of revenue: $2.71B, 17% of revenue
- Interest, other & tax: $629.0M, 4.0% of revenue
Kept 24% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 29, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $15.58B$15.05B | +3.5% |
| Cost of Revenue | $2.71B— | — |
| Gross Profit | $12.87B— | — |
| SG&A Expenses | $4.50B$3.98B | +13.0% |
| Operating Expenses | $11.27B$9.51B | +18.5% |
| Operating Income | $4.31B$5.54B | −22.2% |
| Interest Expense | $610.00M$604.00M | +1.0% |
| Net Income | $3.68B$4.63B | −20.4% |
| EPS (Basic) | $4.07$4.82 | −15.6% |
| EPS (Diluted) | $4.04$4.79 | −15.7% |
| Shares Outstanding (Basic) | 905.00M960.00M | −5.7% |
| Shares Outstanding (Diluted) | 912.00M965.00M | −5.5% |
05—Questions
Frequently Asked Questions
What were Amgen's main revenue drivers in 2011?
Amgen's primary revenue drivers in 2011 were its established biologics: Neulasta®/NEUPOGEN® (sales of $5.2 billion) and Enbrel® (sales of $3.7 billion). The company also saw significant growth from newer products like Prolia® and XGEVA®, contributing over $550 million combined in their early market phases.
How did Amgen manage its capital and return value to shareholders in 2011?
Amgen demonstrated a strong commitment to capital return by initiating its first-ever quarterly cash dividends, totaling $500 million for the year. Additionally, the company aggressively repurchased its own stock, spending $8.3 billion to buy back approximately 15% of its outstanding shares, reflecting confidence in its long-term value.
What were the major financial risks or challenges Amgen faced in 2011?
Amgen faced several significant challenges. A $780 million charge was incurred to settle allegations related to sales and marketing practices. Sales of its Erythropoiesis-Stimulating Agents (ESAs), Aranesp® and EPOGEN®, declined due to updated FDA label changes and changes in reimbursement policies. Furthermore, the company anticipated increasing competition from biosimilars and the impact of patent expirations on its key products in the coming years.
Did Amgen make any strategic acquisitions or investments in 2011?
Yes, Amgen made strategic acquisitions in 2011 to bolster its pipeline and market presence. It acquired BioVex Group, Inc., a company developing cancer and infectious disease treatments, and Laboratório Químico Farmacêutico Bérgamo Ltda, a Brazilian pharmaceutical company. Amgen also announced an agreement to acquire Micromet, Inc. in early 2012.
06—Continue